TD Asset Management Inc. trimmed its holdings in CytomX Therapeutics Inc (NASDAQ:CTMX) by 23.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 46,582 shares of the biotechnology company’s stock after selling 13,900 shares during the period. TD Asset Management Inc. owned 0.10% of CytomX Therapeutics worth $501,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. BNP Paribas Arbitrage SA raised its holdings in shares of CytomX Therapeutics by 84,072.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 9,248 shares during the period. Legal & General Group Plc boosted its position in CytomX Therapeutics by 18.6% during the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 1,306 shares during the period. Deltec Asset Management LLC acquired a new position in CytomX Therapeutics during the 1st quarter worth $129,000. Metropolitan Life Insurance Co. NY boosted its position in CytomX Therapeutics by 376.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 10,650 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its position in CytomX Therapeutics by 18.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 15,904 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 2,478 shares during the period. 81.83% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CytomX Therapeutics stock traded up $0.13 on Monday, reaching $11.35. 302,872 shares of the company were exchanged, compared to its average volume of 460,929. CytomX Therapeutics Inc has a fifty-two week low of $8.94 and a fifty-two week high of $27.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.21 and a quick ratio of 4.21. The stock has a market cap of $514.28 million, a price-to-earnings ratio of -5.59 and a beta of 0.64. The business has a fifty day simple moving average of $10.61.
A number of analysts have recently commented on CTMX shares. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 5th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of CytomX Therapeutics in a research note on Wednesday, April 3rd. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Nomura dropped their price objective on CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. Finally, Cantor Fitzgerald started coverage on CytomX Therapeutics in a research note on Monday, May 13th. They issued an “overweight” rating and a $21.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $20.72.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Story: No Load Funds
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.